PMVP shows severe financial deterioration with operating cash flow worsening by 43.5% to -$73.6M while stockholders' equity declined 40.5% to $104.7M, indicating accelerating cash burn amid clinical trial progression.
The company is burning through cash at an alarming rate with net losses increasing to -$77.7M, driven by 19.4% higher R&D expenses for their rezatapopt clinical trials. While they achieved positive regulatory milestones including FDA orphan drug designation and plan an NDA filing in Q1 2027, the financial runway is rapidly shrinking with total assets declining 39.1% to $116.6M.
PMVP's financial position deteriorated significantly across all metrics, with operating cash flow burning 43.5% faster at -$73.6M and stockholders' equity declining 40.5% to $104.7M. The company's total assets contracted 39.1% to $116.6M while R&D expenses increased 19.4% to fund clinical trials, resulting in net losses widening 32.4% to -$77.7M. This pattern signals accelerating cash consumption despite reduced capital expenditures, raising concerns about financial sustainability as the company advances toward regulatory milestones.
Capex reduced 95.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow fell 43.5% — earnings quality concerns; investigate working capital changes and non-cash items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 39.1% — asset sales, write-downs, or balance sheet optimization underway.
Current assets declined 34.4% — monitor working capital adequacy and short-term liquidity.
Net income declined 32.4% — review whether driven by operations, interest costs, or non-recurring items.
Liabilities reduced 22.1% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
R&D investment increased 19.4% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →